Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist

OSAKA, Japan, /PRNewswire/ — Shionogi & Co., Ltd. (hereafter “Shionogi" or “the Company") announces that the Company has concluded an agreement with Eddingpharm (hereafter “Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®).

Read more: https://prn.to/2XONsh1

迴響已關閉。

在 WordPress.com 建立網站或網誌

向上 ↑

%d 位部落客按了讚: